Novo Nordisk A/S (BVMF:N1VO34)

Market Cap	1.35T
Revenue (ttm)	264.23B
Net Income (ttm)	86.88B
Shares Out	n/a
EPS (ttm)	19.54
PE Ratio	15.58
Forward PE	15.82
Dividend	0.87 (2.28%)
Ex-Dividend Date	Aug 15, 2025

Volume	71,960
Average Volume	55,492
Open	39.83
Previous Close	38.18
Day's Range	39.49 - 41.70
52-Week Range	28.54 - 67.84
Beta	0.36
RSI	60.99
Earnings Date	Feb 4, 2026

About Novo Nordisk

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1923
• Employees: 77,349
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: N1VO34

Financial Performance

In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.

Financial numbers in DKK